Miro Venturi – CEO, Sintetica
Dr Miro Venturi of Swiss injectable anaesthetics and analgesics specialist Sintetica outlines his career journey, why personalised medicine is about taking a holistic view across the entire patient journey, and…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Dr Miro Venturi of Swiss injectable anaesthetics and analgesics specialist Sintetica outlines his career journey, why personalised medicine is about taking a holistic view across the entire patient journey, and…
Nerum Pharmaceuticals, a Switzerland-based start-up, is supplying high-grade cannabis products to nine countries around the world. CEO and Co-Founder Alex Pombo highlights how the company leverages their unique Swiss-Colombia connection,…
Eric ten Kate, VP for Global Life Science at logistics and distribution firm Agility, highlights how the company responded to the unprecedented challenges thrown up by the COVID-19 pandemic and…
Redalpine Venture Partners’ Dr Michael Sidler highlights some of the key trends in the European biotech VC space, the funding and operational strategies that successful start-ups in Europe are utilising,…
Dr Remo Gujer gives an overview of the BMS footprint in Switzerland and Austria, the ongoing integration of legacy Celgene operations, market access challenges, clinical trials, and the importance of…
Laurent Massuyeau introduces Swiss biosimilar commercialisation specialist iQone healthcare, why it made sense to base the company in Switzerland, its partnership deal with Korean biosimilar giant Celltrion, and where iQone’s…
After an illustrious career in oncology R&D, contributing greatly to the development of cutting-edge cancer therapies at Novartis and Gilead, Alessandro Riva, MD joined biotech Ichnos Sciences as its founding…
Thomas F. Schmidt, country manager of Roche Pharma in its home market of Switzerland discusses adjusting to his first role in general management, the particularities of the Swiss market, and…
Andrea Emilio Rizzoli of the Dalle Molle Institute for Artificial Intelligence, among the top 10 in the world in its field of research, outlines the focus of the Institute today,…
This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews…
hystrix medical is an online contracting marketplace for medical devices and replenishing/repeat purchase products in hospitals. CEO Philippe Hügli explains the company’s origins and model today, his ambitions beyond the…
Biotech veteran Brian O’Callaghan introduces ObsEva – a Swiss-based firm focused on women’s health –, his motivations to join the company – which is on the verge of transforming into…
See our Cookie Privacy Policy Here
